📊 CRVO Key Takeaways
Is CervoMed Inc. (CRVO) a Good Investment?
CervoMed is a pharmaceutical company in severe financial distress with dramatically deteriorating fundamentals. Revenue collapsed 58.9% YoY to just $4.0M while operating losses expanded to -$28.3M, indicating the company is burning cash at an unsustainable rate with no clear path to profitability. Despite adequate near-term liquidity, the company's burn rate of -$23.4M in operating cash flow against minimal revenue suggests runway of approximately 5 months at current levels.
CervoMed's fundamentals are extremely weak, with revenue down 58.9% year over year, zero gross profit, and deeply negative operating and net margins that indicate the current business model is not generating sustainable economics. While the balance sheet is relatively clean with no long-term debt and a solid current ratio, the company's cash burn is severe versus its cash balance, creating meaningful funding risk unless operating performance improves materially.
Why Buy CervoMed Inc. Stock? CRVO Key Strengths
- Strong current ratio of 4.91x provides near-term liquidity cushion
- No long-term debt reduces financial obligations and restructuring complexity
- Cash reserves of $8.2M provide some runway for operations or strategic pivots
- Debt-free balance sheet with no long-term debt reduces financial leverage risk
- Current and quick ratios of 4.91x indicate near-term liabilities are currently manageable
- Positive reported revenue base, however small, provides some operating activity rather than being entirely pre-revenue
CRVO Stock Risks: CervoMed Inc. Investment Risks
- Massive operating losses of -$28.3M against $4.0M revenue indicates core business failure
- Operating cash burn of -$23.4M annually with only $8.2M cash will exhaust liquidity in ~3-5 months without capital injection
- Zero gross profit and 0% gross margin indicate product offerings generate no value or are not selling
- Severe negative profitability margins (-706% operating margin, -673% net margin) reflect fundamental business model breakdown
- Revenue decline of 58.9% YoY demonstrates accelerating commercial failure, not temporary headwinds
- Revenue contraction of 58.9% year over year signals weak growth quality and poor commercial traction
- Operating loss of $28.29M and free cash flow of -$23.90M show unsustainably high cash burn
- ROE of -148.0% and ROA of -117.9% reflect severe value destruction and inefficient asset use
Key Metrics to Watch
- Monthly operating cash burn rate and runway calculation
- Revenue stabilization and customer acquisition trends
- Gross margin improvement indicating product viability
- Insider trading activity suggesting management confidence or exit strategy
- Quarterly operating cash burn relative to cash and equivalents
- Revenue stabilization and improvement in operating margin
CervoMed Inc. (CRVO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.91x current ratio provides a solid financial cushion.
CRVO Profit Margin, ROE & Profitability Analysis
CRVO vs Healthcare Sector: How CervoMed Inc. Compares
How CervoMed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CervoMed Inc. Stock Overvalued? CRVO Valuation Analysis 2026
Based on fundamental analysis, CervoMed Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CervoMed Inc. Balance Sheet: CRVO Debt, Cash & Liquidity
CRVO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CervoMed Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $1,946,859.00 reflects profitable operations.
CRVO Revenue Growth, EPS Growth & YoY Performance
CRVO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $322.6K | -$4.8M | N/A |
| Q2 2025 | $1.8M | -$2.3M | N/A |
| Q1 2025 | $1.9M | -$2.5M | N/A |
| Q3 2024 | $1.5M | $190.5K | $-0.55 |
| Q2 2024 | $1.7M | -$1.4M | N/A |
| Q1 2024 | $1.4M | -$534.3K | N/A |
| Q3 2023 | N/A | $190.5K | $-0.70 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CervoMed Inc. Dividends, Buybacks & Capital Allocation
CRVO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CervoMed Inc. (CIK: 0001053691)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRVO
What is the AI rating for CRVO?
CervoMed Inc. (CRVO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRVO's key strengths?
Claude: Strong current ratio of 4.91x provides near-term liquidity cushion. No long-term debt reduces financial obligations and restructuring complexity. ChatGPT: Debt-free balance sheet with no long-term debt reduces financial leverage risk. Current and quick ratios of 4.91x indicate near-term liabilities are currently manageable.
What are the risks of investing in CRVO?
Claude: Massive operating losses of -$28.3M against $4.0M revenue indicates core business failure. Operating cash burn of -$23.4M annually with only $8.2M cash will exhaust liquidity in ~3-5 months without capital injection. ChatGPT: Revenue contraction of 58.9% year over year signals weak growth quality and poor commercial traction. Operating loss of $28.29M and free cash flow of -$23.90M show unsustainably high cash burn.
What is CRVO's revenue and growth?
CervoMed Inc. reported revenue of $4.0M.
Does CRVO pay dividends?
CervoMed Inc. does not currently pay dividends.
Where can I find CRVO SEC filings?
Official SEC filings for CervoMed Inc. (CIK: 0001053691) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRVO's EPS?
CervoMed Inc. has a diluted EPS of $-1.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRVO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CervoMed Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRVO stock overvalued or undervalued?
Valuation metrics for CRVO: ROE of -148.0% (sector avg: 15%), net margin of -673.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRVO stock in 2026?
Our dual AI analysis gives CervoMed Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRVO's free cash flow?
CervoMed Inc.'s operating cash flow is $-23.4M, with capital expenditures of $447.8K. FCF margin is -596.5%.
How does CRVO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -673.1% (avg: 12%), ROE -148.0% (avg: 15%), current ratio 4.91 (avg: 2).